About this trial
This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.
Eligibility criteria
Qualifiers
Diagnosis of primary leiomyosarcoma of the ovary;
Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available.
Aged between 18 and 99 years
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed